Login / Signup
Authors' Reply to "Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease".
Robert Battat
Published in:
Inflammatory bowel diseases (2022)
Keyphrases
</>
rheumatoid arthritis
open label
drug induced
emergency department
clinical trial